

2023

EXECUTIVE REPORT

INCLIVA | VLC
Biomedical Research Institute

INCLIVA | VLC

Biomedical Research Institute

EXECUTIVE REPORT

2023



PRESENTATION

1

STRUCTURE OF INCLIVA

2

SCIENTIFIC PRODUCTION

3

SCIENTIFIC ACTIVITY

4

KNOWLEDGE TRANSFER ACTIVITIES

5

NETWORKS AND PLATFORMS

6

HUMAN RESOURCES AT INCLIVA BY
GENDER PERSPECTIVES

7

FINANCIAL RESOURCES

8

COMMUNICATION

9

index



EXECUTIVE REPORT 2023

1. PRESENTATION

The Hospital Clínico Universitario of Valencia Research Foundation was constituted in the year 2000 as the first Valencian research foundation affiliated to a public hospital. Ten years later, various centers of excellence in biomedical research from the University of Valencia and Carlos Simón Foundation joined the Foundation through the establishment of specific agreements, and thus INCLIVA Biomedical Research Institute was created.

INCLIVA's main aims are to manage the biomedical research carried out by the Hospital Clínico Universitario de Valencia and its Health Department, and to encourage teaching and scientific activities, thus improving patient treatment and knowledge sharing.

In 2011 INCLIVA was accredited as a Health Research Institute by the Ministry of Science and Innovation (Ministerio de Ciencia e Innovación) thus obtaining preferential treatment from the Carlos III Health Institute (Instituto de Salud Carlos III), in recognition of its excellence in research.

In 2021 INCLIVA received the official notification of renewal of its accreditation as Health Research Institute for the next five years.



2. STRUCTURE OF INCLIVA

INCLIVA Biomedical Research Institute articulates its research in 4 R&I areas organised into 54 research groups, of which 12 are emerging, and 7 associated clinical groups. Through their scientific activity, all the groups work towards a common goal: to respond to healthcare needs and improve the R&D&i system.



Mission, Vision and Values

Mission Research to solve unresolved medical needs of the public.	Vision To be a centre of international reference in translational research and health innovation aimed at preserving and improving the health of citizens.
Values Citizen orientation and commitment to society: to seek solutions to society's main health problems in a transparent, environmentally friendly and sustainable manner. Excellence: permanent orientation towards scientific and management excellence. Innovation: orientation towards innovation and the transfer of results. Responsibility: Equal opportunities, attracting young talent and retaining consolidated talent.	

Tranversal scientific programmes

In line with its commitment to promote collaborative and multidisciplinary research, INCLIVA has established a structure organised around seven scientific programmes aimed at specific diseases from a translational perspective:

Programme in
Overweight and
Cardiovascular
and Renal Risk

Programme
in Detection
and Control
of Ventricular
Dysfunction

Programme in
Rare Diseases

Programme in
Neurological
Impairment

Programme in
Translational
Oncology

Programme in
Reproductive
Medicine

Programme
in Aging and
Associated
Diseases



1

2

3

4

5

6

7

8

9

Cardiovascular Area

Coordinator: Mr. Francisco Javier Chorro

Mission: to contribute to the study of different aspects of cardiovascular disease [CVD] from its origins to its consequences.



12 research groups

- Research Group on Cardiometabolic Risk and Diabetes
José Tomás Real Collado, Sergio Martínez Hervás, Juan Francisco Ascaso Gimilio
- Genomics and Diabetes Unit
Felipe Javier Chaves Martínez
- Research Group on Cardiac Experimental Electrophysiology
Francisco Javier Chorro Gascó, Antonio M. Alberola Aguilar, Luis Such Belenguer
- Research Group on Endothelial Cells (LINCE)
Carlos Hermenegildo Caudevilla
- Research Group on Clinical Cardiology
Juan Sanchis Forés
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents
Empar Lurbe i Ferrer
- Cardiometabolic Research Group on Primary Care
Jorge Navarro Pérez
- Research Group on the Study of Cardiometabolic and Renal Risk
Josep Redón i Mas
- Research Group on Vascular Function
José M^a Vila Salinas, M^a Dolores Mauricio Aviñó
- Research Group on Pediatric Nutrition
Cecilia Martínez Costa, Javier Buesa Gómez
- Group on Translational Research in Ischemic Heart Disease
Vicente Bodí Peris
- Research Group on Heart Failure
Julio Núñez Villota

emerging group

195

Publications

Average

IF

10.8

65

Research
projects

Oncology Area

Coordinator: Mr. Andrés Cervantes

Mission: to contribute to the study of different aspects of oncological diseases, at the stage of diagnosis and molecular characterization and selection of specific molecular targets of therapeutic interest.



11 research groups

- Research Group on Histopathology and Tissue Engineering
Carmen Carda Batalla, Manuel Mata Roig, Amando Peydró Olaya
- Research Group on Central Nervous System Tumors
Miguel Cerdá Nicolás
- Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors – InDeST
Andrés Cervantes Ruipérez
- Research Group on Breast Cancer Biology
Ana Lluch Hernández, Pilar Eroles Asensio
- Research Group on Skin Cancer
José Carlos Monteagudo Castro
- Translational Research Group on Pediatric Solid Tumors
Samuel Navarro Fos, Rosa Noguera Salvá
- Research Group on Hematopoietic Transplantation
Carlos Solano Vercet
- Research Group on Lymphoproliferative Disorders
M^a José Terol Casterá
- Research Group on Myeloid Neoplasms
Mar Tormo Díaz, Juan Carlos Hernández Boluda
- Research Group on Molecular Imaging and Metabolomics
Daniel Monleón Salvadó
- Research Group on Molecular Microbiology and Microbial Pathogenesis
David Navarro Ortega

emerging group



1

2

3

4

5

6

7

8

9

Metabolism and Organic Damage Area

Coordinator: Mr. José Viña

Mission: to contribute to the study of the etiology, pathophysiology and diagnosis mechanisms or treatment of various metabolic diseases; or those that generate organ damage as a fundamental link of its trigger action.



20 research groups

- Research Group on Genetics of Osteoporosis
Miguel Ángel García Pérez
- Research Group on Neurological Impairment
Carmina Montoliu Félix
- Research Group on Inflammation
María Jesús Sanz Ferando, Esteban Morcillo Sánchez
- Research Group on Psychiatry and Neurodegenerative Diseases
Julio Sanjuan Arias, Juan Nácher Roselló
- Research Group on Respiratory Diseases
Jaime Signes-Costa Miñana
- Research Group on Tissular Biochemistry
Juan R. Viña Ribes, Teresa Barber Ballester, Elena Ruiz García-Trevijano
- Research Group on Aging and Physical Activity
José Viña Ribes
- Research Group on Anesthesiology and Reanimation
Rafael Badenes Quiles
- Research Group on Human Translational Genomics
Rubén D. Artero Allepuz, Manuel Pérez Alonso
- Research Group on General and Digestive Surgery
Joaquín Ortega Serrano, Luis Sabater Ortí
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders [TMAP]
Rafael Tabarés Seisdedos, Manuel Gómez Beneyto, Vicent Balanzá Martínez
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress
Federico V. Pallardó Calatayud

- Research Group on Inflammation: Metabolism and Organic Damage Line
Laura Piqueras Ruiz
- Research group on Metabolic Diseases
Herminia González Navarro
- Research Group on Rare Respiratory Diseases (RRD)
Francisco Dasí Fernández
- Research Group on Healthy Aging (MiniAging)
Consuelo Borrás Blasco
- Research Group on Exercise, Nutrition and Healthy Lifestyle
M^a Carmen Gómez Cabrera
- Research Group on Epigenomics and Translational Epigenetics
José Luis García Giménez
- Research Group in Medical Chemistry for Drug Development
Nuria Cabedo Escrig
- Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases
– NeuroFisER
Pilar González Cabo

emerging groups

248
Publications

Average
IF
7.63

106
Research
projects



Reproductive Medicine Area

Coordinator: Mr. Carlos Simón


Mission: to advance in knowledge of human reproduction for translational application, improving the efficiency of assisted reproduction treatment and reducing adverse effects.



4 research groups

- Research Group on Women's Health
Antonio Cano Sánchez, Juan José Tarín Folgado
- Research Group on Reproductive Medicine
Carlos Simón Vallés
- Research Group on Therapies Against Endometriosis and Endometrial Cancer
Raúl Gómez Gallego
- Research Group on Maternal Fetal Communication
Felip Vilella Mitjana

emerging groups



Associated Clinical Groups Area

7 research groups

- Research Group on Research in Care. INVESTENF-INCLIVA
M^a José Gastaldo Zaragoza
- Associated Clinical Group in Urology
José Martínez Jabaloyas
- Associated Clinical Group in Digestive Medicine
Isabel Pascual Moreno
- Associated Clinical Group in Otorhinolaryngology
Jaime Marco Algarra
- Associated Clinical Group in Traumatology and Orthopedics
Antonio Silvestre Muñoz
- Associated Clinical Group in Neurology
José Miguel Láinez Andrés
- Associated Clinical Group in Pharmacy
Manuel Alós Almiñana

13

Publications

Average
IF
3.45

8

Research
projects



1

2

3

4

5

6


7

8

9

3. SCIENTIFIC PRODUCTION

Indexed publications




The number of publications in 2023 was 689 with a cumulative impact factor of 5,068.6 which translates into an average impact factor 9,785.




Quartile distribution

In the last year, about 87% of the papers that were published in indexed journals belong to the first and second quartiles of their corresponding thematic categories:




Doctoral thesis



4. SCIENTIFIC ACTIVITY


Research projects

In 2023, 135 public projects (112 nacional and 23 international) were active in competitive bidding, of which 36 new competitive public projects were awarded (32 national and 4 international).




Clinical trials and other studies

As a result of its activity along 2023, INCLIVA has managed a total of **175** new studies (clinical trials and observational studies).



Evolution of clinical trial distribution by phase

During the period 2019-2023, INCLIVA prioritises Phase I and Phase II trials, fulfilling its objective of developing clinical research in its initial phases and thus contributing to translational research that moves scientific knowledge from the laboratory bench to the patient's bedside.




Phase I oncology clinical trials

INCLIVA is the only Biomedical Research Institute in Valencia performing Phase I cancer clinical trials, and one of the few in Spain. Phase I trials are those in which a substance or product is tested in humans for the first time.

In 2023, INCLIVA is conducting, through the Oncology Department, 229 clinical trials, 164 of them related to treatment in the early stages of testing (85 phase I or “first in human” and 79 phase II).

The following image shows the oncology clinical trials in phase I in the last 5 years.




Initiatives for research promotion

In order for researchers to acquire new knowledge for clinical and research techniques, during 2023 INCLIVA has funded 24 grants in centers of excellence.

In addition, 4 researchers of INCLIVA carried out internships in external centers and 4 others have been granted scholarships in INCLIVA.

93 students of Vocational Qualification, Degree or Master have been accepted for training internships in different research groups in INCLIVA during 2023.




5. KNOWLEDGE TRANSFER ACTIVITIES

INCLIVA Biomedical Research Institute is fully committed to transfer the knowledge created both to the National Health System and to the industrial sector in order to fulfil its organizational mission.

Knowledge transfer to the National Health System

Clinical guidelines and consensus documents are one of the best indicators of knowledge transfer from research to clinical practice. The guidelines published in 2023 in indexed journals in which INCLIVA-affiliated authors have participated are shown below.



Innovation and Knowledge transfer

INCLIVA's Innovation Unit supports INCLIVA professionals in the development of translational research to achieve greater impact on society, promotes innovation and collaboration with research centres and industrial partners, and assesses the viability of innovative ideas at different stages to ensure that only the best ideas are launched on the market








6. NETWORKS AND PLATFORMS

Cooperative research networks

The Carlos III Health Institute develops the creation of stable research network structures such as CIBER (Network of Centres for Biomedical Research).

INCLIVA participates in this research structure through its associated groups.

Research Area	INCLIVA PI	Scientific Network		Reference
Cardiovascular	Mr. José Tomás Real Collado	CIBERdem	 DEM	CB07/08/0018
	Mrs. Empar Lurbe i Ferrer	CIBERobn		CB06/03/0039
	Mr. Francisco Javier Chorro Gascó	CIBERcv	 CV	CB16/11/00486
	Mr. Juan Sanchis Forés	CIBERcv		CB16/11/00420
Metabolism and Organ Damage	Mr. Federico V. Pallardó Calatayud	CIBERer	 ER	CB06/07/0073
	Mr. Juan Nácher Roselló	CIBERsam		CB07/09/006
	Mr. Rafael Tabarés Seisdedos	CIBERsam	 SAM	CB07/09/0021
	Mr. José Viña Ribes	CIBERfes		CB16/10/00435
Oncology	Mr. Andrés Cervantes Ruipérez	CIBERonc	 FES	CB16/12/00473
	Mrs. Rosa Noguera Salvá	CIBERonc		CB16/12/00484

Associated networks and platforms

Nationals



Internationals



1

2

3

4

5

6

7

8

9

7. HUMAN RESOURCES AT INCLIVA BY GENDER PERSPECTIVE

HR Excellence in Research


In 2019, INCLIVA obtained the HR Excellence in Research (HRS4R) quality seal, which recognizes the ability to attract talent, generate a favorable work environment, promote research and innovation, and enhance the careers of researchers within the European framework.



HR EXCELLENCE IN RESEARCH

Breakdown of Research Group staff


A total of 748 researchers belong to consolidated, emerging and associated research groups, and whose EURAXESS profile distribution is as follows.



Women and men working together at INCLIVA

As part of its commitment to contribute towards guaranteeing real equality between women and men, INCLIVA's Board of Trustees has approved the II INCLIVA Equality Plan (2020-2024) following approval by the Equality Committee.

In 2023, a total of 278 employees joined INCLIVA, of whom 73% are women. The percentage of women hired has increased every year for the last three years.




Women Men

8. FINANCIAL RESOURCES


INCLIVA's funding

INCLIVA's funding during 2023 totaled €19,707,737.



Funding Sources in 2023


The funds come from competitive sources and grants, private funding sources and donations.



9. COMMUNICATION

Press office


During 2023, INCLIVA issued a total of **134** press releases.



Social Media users 2023



INCLIVA Website 2023



Outreach 2023





INCLIVA | VLC

Biomedical Research Institute

Avda. Menéndez Pelayo, 4 accesorio · 46010 Valencia (España)

Tel. 34 96 197 35 17 Fax 34 96 197 35 40

www.incliva.es incliva@incliva.es